kanitinib (CX1003) / Konruns Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
kanitinib (CX1003) / Konruns Pharma
NCT02916095: Kanitinib in Treating Patients With Advanced Solid Tumors

Completed
1
9
RoW
Kanitinib, CX1003
Beijing Konruns Pharmaceutical Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumors
01/20
07/20
NCT04093466: A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors

Recruiting
1
126
RoW
CX1003, kanitinib
Beijing Konruns Pharmaceutical Co., Ltd., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, West China Hospital, Beijing Tongren Hospital
Advanced Solid Tumor
11/22
11/22

Download Options